Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2023 | 96 | 7.410 |
Why?
|
| Medication Adherence | 5 | 2024 | 69 | 2.150 |
Why?
|
| Receptor, ErbB-2 | 9 | 2023 | 17 | 2.050 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2019 | 6 | 1.670 |
Why?
|
| Female | 30 | 2024 | 2523 | 1.540 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 69 | 1.530 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2022 | 13 | 1.520 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 13 | 1.490 |
Why?
|
| Humans | 34 | 2024 | 4936 | 1.400 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2022 | 14 | 1.390 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2022 | 22 | 1.320 |
Why?
|
| Oncogene Proteins | 2 | 2021 | 2 | 1.240 |
Why?
|
| Aged | 11 | 2024 | 703 | 0.930 |
Why?
|
| Lung Neoplasms | 3 | 2024 | 25 | 0.900 |
Why?
|
| Thalidomide | 1 | 2024 | 3 | 0.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 15 | 0.840 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 10 | 0.830 |
Why?
|
| Estrogen Receptor alpha | 2 | 2022 | 22 | 0.830 |
Why?
|
| Social Class | 1 | 2024 | 20 | 0.820 |
Why?
|
| Receptors, Estrogen | 7 | 2020 | 14 | 0.790 |
Why?
|
| Cell Line, Tumor | 7 | 2022 | 160 | 0.760 |
Why?
|
| Neoplasms | 2 | 2015 | 90 | 0.740 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2022 | 1 | 0.720 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2022 | 2 | 0.720 |
Why?
|
| Tinnitus | 1 | 2021 | 1 | 0.710 |
Why?
|
| Mice | 9 | 2022 | 685 | 0.700 |
Why?
|
| Retrospective Studies | 6 | 2024 | 341 | 0.700 |
Why?
|
| Cancer Survivors | 2 | 2018 | 14 | 0.680 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 262 | 0.670 |
Why?
|
| Middle Aged | 9 | 2024 | 967 | 0.670 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 2 | 0.640 |
Why?
|
| Medicare | 4 | 2024 | 78 | 0.600 |
Why?
|
| Palliative Care | 1 | 2019 | 4 | 0.600 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 7 | 0.600 |
Why?
|
| Prescription Drugs | 1 | 2019 | 15 | 0.590 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 1 | 0.590 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 23 | 0.570 |
Why?
|
| Quinolines | 1 | 2019 | 21 | 0.570 |
Why?
|
| Animals | 9 | 2022 | 1711 | 0.560 |
Why?
|
| Tamoxifen | 6 | 2022 | 12 | 0.560 |
Why?
|
| Adult | 7 | 2024 | 1567 | 0.530 |
Why?
|
| Cell Proliferation | 5 | 2022 | 115 | 0.530 |
Why?
|
| Mucositis | 1 | 2015 | 1 | 0.470 |
Why?
|
| Glutamine | 1 | 2015 | 4 | 0.460 |
Why?
|
| Febrile Neutropenia | 1 | 2015 | 2 | 0.460 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2015 | 4 | 0.460 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 7 | 0.450 |
Why?
|
| Quinazolines | 2 | 2015 | 2 | 0.420 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2013 | 1 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2013 | 4 | 0.410 |
Why?
|
| Drug Eruptions | 1 | 2013 | 1 | 0.400 |
Why?
|
| Acneiform Eruptions | 1 | 2013 | 1 | 0.400 |
Why?
|
| United States | 4 | 2024 | 495 | 0.390 |
Why?
|
| Cytotoxins | 1 | 2012 | 1 | 0.370 |
Why?
|
| Ketones | 1 | 2012 | 1 | 0.370 |
Why?
|
| Furans | 1 | 2012 | 2 | 0.370 |
Why?
|
| Estradiol | 4 | 2022 | 16 | 0.360 |
Why?
|
| Heterografts | 4 | 2022 | 8 | 0.360 |
Why?
|
| Male | 5 | 2024 | 2491 | 0.340 |
Why?
|
| Estrogens | 3 | 2022 | 21 | 0.330 |
Why?
|
| Signal Transduction | 5 | 2021 | 216 | 0.330 |
Why?
|
| Treatment Outcome | 3 | 2019 | 177 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 4 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 55 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 3 | 0.280 |
Why?
|
| Risk Factors | 4 | 2020 | 159 | 0.280 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 8 | 0.280 |
Why?
|
| Administration, Oral | 2 | 2020 | 33 | 0.270 |
Why?
|
| Postmenopause | 3 | 2023 | 7 | 0.270 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 225 | 0.240 |
Why?
|
| Transcriptome | 2 | 2016 | 43 | 0.230 |
Why?
|
| SEER Program | 1 | 2024 | 7 | 0.220 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 6 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 9 | 0.210 |
Why?
|
| Immunologic Factors | 1 | 2024 | 17 | 0.210 |
Why?
|
| Mice, Nude | 2 | 2021 | 19 | 0.210 |
Why?
|
| Texas | 1 | 2024 | 190 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 5 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 29 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 35 | 0.190 |
Why?
|
| Pandemics | 1 | 2023 | 73 | 0.190 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 12 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 9 | 0.180 |
Why?
|
| Obesity | 1 | 2023 | 115 | 0.180 |
Why?
|
| Prognosis | 3 | 2019 | 60 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 39 | 0.170 |
Why?
|
| G1 Phase | 1 | 2021 | 1 | 0.170 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2021 | 2 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 5 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2021 | 9 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 12 | 0.170 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 35 | 0.170 |
Why?
|
| Mastectomy | 1 | 2020 | 5 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 35 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2020 | 16 | 0.160 |
Why?
|
| Breast | 1 | 2020 | 15 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 269 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 48 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 9 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cancer Pain | 1 | 2019 | 3 | 0.150 |
Why?
|
| Polypharmacy | 1 | 2019 | 8 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 14 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 14 | 0.150 |
Why?
|
| Leukocyte Common Antigens | 1 | 2019 | 3 | 0.150 |
Why?
|
| Keratins | 1 | 2019 | 3 | 0.150 |
Why?
|
| Cell Separation | 1 | 2019 | 7 | 0.150 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 7 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2019 | 9 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 18 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 15 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 4 | 0.150 |
Why?
|
| Cinnamates | 1 | 2018 | 3 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 4 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 2 | 0.140 |
Why?
|
| Aminopyridines | 1 | 2018 | 5 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 8 | 0.140 |
Why?
|
| Thy-1 Antigens | 1 | 2018 | 1 | 0.140 |
Why?
|
| Hyaluronan Receptors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2018 | 31 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 73 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 14 | 0.140 |
Why?
|
| Mutation | 1 | 2019 | 132 | 0.130 |
Why?
|
| Registries | 1 | 2018 | 22 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2020 | 111 | 0.130 |
Why?
|
| Young Adult | 2 | 2019 | 787 | 0.130 |
Why?
|
| Depression | 1 | 2019 | 125 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2016 | 2 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 318 | 0.120 |
Why?
|
| Atrophic Vaginitis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 20 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3 | 0.120 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Taxoids | 1 | 2015 | 4 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2015 | 26 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2015 | 17 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 34 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 48 | 0.110 |
Why?
|
| Blood Component Removal | 1 | 2013 | 1 | 0.100 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 6 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 1 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 5 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 16 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 23 | 0.100 |
Why?
|
| Cytokines | 1 | 2013 | 37 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 83 | 0.080 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 17 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 27 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 59 | 0.060 |
Why?
|
| Time Factors | 2 | 2015 | 163 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2022 | 81 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 2 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 8 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 47 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 65 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 44 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 1 | 0.040 |
Why?
|
| Premenopause | 1 | 2018 | 2 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 2 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 9 | 0.040 |
Why?
|
| CD24 Antigen | 1 | 2018 | 1 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 21 | 0.040 |
Why?
|
| Stem Cells | 1 | 2018 | 33 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 27 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 27 | 0.030 |
Why?
|
| Quality of Life | 1 | 2018 | 87 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 11 | 0.030 |
Why?
|
| Administration, Intravaginal | 1 | 2016 | 1 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 17 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 14 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 3 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 1 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 12 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 54 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 49 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 81 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2013 | 1 | 0.030 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2013 | 1 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2013 | 3 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 4 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 51 | 0.020 |
Why?
|